Lapatinib And Pazopanib Combo Not Found To Improve Outcomes For Patients With Inflamm
 

Inflammatory breast cancer is a very aggressive type of cancer associated with early metastasis and poor survival rates, and the prognosis is even worse for patients with tumors expressing the ErbB2 receptor. The ErbB2-inhibiting drug lapatinib can slow the spread of cancer cells in individuals with advanced breast cancer who have already tried other chemotherapy medications...

More...